Pinned Tweet
ALZpath and Siemens Healthineers have signed a licensing agreement to accelerate global access to blood-based Alzheimer’s disease diagnostic testing.
🔗Read the full press release: alzpath.bio/alzpath-and-siem…
What will it take to scale accurate, accessible blood-based Alzheimer’s testing?
ALZpath Distinguished Scientific Advisor, Dr. Henrik Zetterberg shares his perspective in PMLiVE.
Read Dr. Zetterbergs article now: pmlive.com/intelligence/the-…
We’re thrilled to share that we're expanding our licensing agreement with @Quanterix to advance next generation Alzheimer's disease biomarker research.
🔗Read the full announcement: alzpath.bio/alzpath-and-quan…
#pTau217 #Quanterix
This #WorldAlzheimersMonth, progress in blood based Alzheimer’s testing offers even more reason for hope.
Years of research are moving closer to clinical practice, with the potential to support more accessible assessment and clearer answers for clinicians, patients & families.
Last week, @Roche received FDA clearance for the Elecsys® pTau217 blood test, developed using ALZpath’s proprietary #pTau217 antibody—an important step toward broader access to blood-based Alzheimer’s disease testing and care.
🔗Read the full release: diagnostics.roche.com/us/en/…
Big news from our partners at @BeckmanDx: Beckman Coulter announced CE Mark for its Access p-Tau217 assay, developed using ALZpath’s proprietary pTau217 antibody.
🔗Read the full announcement: prnewswire.com/news-releases…
Just 1 week until #AAIC26.
ALZpath is looking forward to attending AAIC 2026 next week in London.
If you’re attending, we welcome the opportunity to connect. To schedule a time with the ALZpath team, reach out to Jacob Hunter at [email protected].
We'll see you there!
ALZpath featured in Reuters following announcement of global licensing agreement with @AbbottNews , helping advance blood-based Alzheimer’s disease testing worldwide.
Read more: reuters.com/world/alzpath-si…
#AlzheimersDisease #pTau217 #Diagnostics
ALZpath Signs Global Licensing Agreement with @AbbottNews to Advance Blood-Based Alzheimer's Disease Testing
The agreement will incorporate ALZpath’s proprietary pTau217 antibody into development of an IVD test for use on Abbott’s Alinity ci-series systems.
We’re attending AAIC 2026! 🧠
Join ALZpath in London, July 12-15th.
Attending AAIC 2026 and interested in connecting? Reach out to Jacob Hunter at [email protected] to schedule a meeting with our team.
We'll see you there!
🧠 June is Alzheimer's & Brain Awareness Month.
This month, we recognize the individuals, families, caregivers and communities impacted by Alzheimer's disease, along with those dedicated to advancing awareness, research, diagnosis, and care.
#AlzheimersDisease #ENDALZ
ALZpath retweeted
🚨What if Alzheimer’s could be detected years - even decades - before symptoms begin? 🧠
That future is closer than most people realize. 🚀
On the latest episode of @ProgressPotent1 I sat down with Mike Banville, CEO of @AlZpath
After decades scaling global businesses, Mike is now focused on one of healthcare’s biggest challenges:
👉Making early, accessible Alzheimer’s detection a reality.
We explore:
• How ALZpath’s pTau217 antibody is enabling blood tests that may rival PET scans and spinal taps;
• Why earlier detection could reshape clinical trials, treatment timing, and patient outcomes;
• The bigger shift toward precision medicine and proactive brain health;
This isn’t just about diagnostics - it’s about changing when the fight against Alzheimer’s begins. ⚕️
#Alzheimers #BrainHealth #Biotech #EarlyDetection #PrecisionMedicine #HealthcareInnovation #Dementia #Neuroscience #Longevity @FINNPartners @FPIPR @SiemensHealth @Roche @RocheDiaUSA @BCILifeSciences @BeckmanDx
ALZpath retweeted
@Roche received CE Mark approval for the Elecsys pTau217 blood test, developed with @EliLillyandCo & powered by ADDF-funded @AlZpath’s pTau217 antibody. The approval marks another important step toward broader access to scalable Alzheimer’s diagnostics. reut.rs/4dBdopf
With @adpdnet 2026 underway in Copenhagen, research featuring ALZpath’s pTau217 antibody appears across 29 scientific presentations.
Highlights from this week’s program below.
🔗 Read more: alzpath.bio/broad-ad-pd-2026…
1 week until AD/PD™ 2026 🧠
The global Alzheimer’s disease and Parkinson’s disease community will gather in Copenhagen, March 17–21.
Attending and want to connect? Reach out to Jacob Hunter at [email protected] to schedule a meeting.
We’re attending AD/PD 2026! ALZpath is excited to join the AD/PD™ 2026 Conference, March 17–21, in Copenhagen, Denmark.
If you will be attending and would like to connect, please reach out to Jacob Hunter at [email protected] to schedule a meeting.
#ADPD2026
🧠The words we use around brain health matter.
ALZpath has joined the Initiative to Change the “D-Word,” committing to remove outdated, stigmatizing language around cognitive impairment.
🔗Learn more in the full press release: alzpath.bio/alzpath-commits-…
We’re pleased to participate in the Global BioInnovation Forum today during @jpmorgan #JPM2026.
Our CEO Michael Banville will join a session moderated by @Gil_Bashe on how blood-based diagnostics are reshaping Alzheimer’s detection.
🕝 2:30 PM PT
🔗 1businessworld.com/global-bi…
ALZpath retweeted
Bold move aims to scale blood-based diagnostics globally as demand for earlier, more accessible Alzheimer’s disease detection accelerates
longevity.technology/news/ne…
#longevity #Alzheimers #AlzheimersTesting #BloodTest #EarlyDetection #Neurodegeneration #HealthTech #MedTech
